Loading patent…
AssigneesInstitut Pasteur, Centre National De La Recherche Scientifique, MINISTÈRE DES ARMÉES—Direction Centrale du Service de Santé des Armées
InventorsFrederic Tangy, Anastassia Komarova, Marie Mura, Chantal Combredet
Estimating the term…
The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5′ copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5′ copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and/or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.
A method of enhancing an immune response elicited by an immunogenic composition, comprising administering the immunogenic composition with an adjuvant, wherein the adjuvant is a defective interfering (DI) genome (DI-RNA) of a measles virus genome in the form of a non-encapsidated RNA,
A method of enhancing the immunogenicity of an immunogenic composition which comprises adding an adjuvant to the immunogenic composition wherein the adjuvant is a defective interfering (DI) genome (DI-RNA) of a measles virus genome in the form of a non-encapsidated RNA,
A defective interfering genome of a measles virus in the form of a non-encapsidated DI-RNA which has a sequence of 450 nucleotides in length, a breakpoint at nucleotide 15557 of sequence GenBank AF266291.1 and a re-initiation site at nucleotide 15783 of sequence GenBank AF266291.1 and has in its structure a ssRNA loop of 226 nucleotides and a dsRNA stem of 112 nucleotides, wherein the DI-RNA hybridizes with forward primer consisting of the sequence
Dependencies are inferred from the claim text.